Hologic, Inc. [HOLX] stock prices are up 1.55% to $77.35 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The HOLX shares have gain 3.08% over the last week, with a monthly amount glided 2.64%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, March 2024, Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing. In a post published today on Yahoo Finance, Results From a Large-Scale Prospective Study Investigating Long-Term Anti-Estrogen Therapy Recommendations Published in JNCCN — Journal of the National Comprehensive Cancer Network.
From an analyst’s perspective:
Hologic, Inc. [NASDAQ: HOLX] stock has seen the most recent analyst activity on July 14, 2023, when Needham upgraded its rating to a Buy but kept the price target unchanged to $95 for it. Previously, RBC Capital Mkts started tracking the stock with Sector Perform rating on December 07, 2022, and set its price target to $75. On October 13, 2022, Mizuho initiated with a Buy rating and assigned a price target of $75 on the stock. UBS started tracking the stock assigning a Neutral rating and suggested a price target of $73 on July 20, 2022. BofA Securities downgraded its rating to a Neutral and reduced its price target to $75 on July 20, 2022. BTIG Research downgraded its rating to Neutral for this stock on July 18, 2022. In a note dated April 25, 2022, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $75.
The stock price of Hologic, Inc. [HOLX] has been fluctuating between $64.02 and $87.88 over the past year. Currently, Wall Street analysts expect the stock to reach $81.2 within the next 12 months. Hologic, Inc. [NASDAQ: HOLX] shares were valued at $77.35 at the most recent close of the market. An investor can expect a potential return of 4.98% based on the average HOLX price forecast.
Analyzing the HOLX fundamentals
The Hologic, Inc. [NASDAQ:HOLX] reported sales of 3.97B for trailing twelve months, representing a drop of -5.69%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at 0.19%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.1 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.55.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 76.75 points at the first support level, and at 76.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 77.66, and for the 2nd resistance point, it is at 77.97.
Hologic, Inc. [HOLX] reported earnings per share of $0.98 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.95/share, meaning a difference of $0.03 and a surprise factor of 3.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.89 per share as compared to estimates of $0.84 per share, a difference of $0.05 representing a surprise of 6.00%.
Ratios To Look Out For
It’s worth pointing out that Hologic, Inc. [NASDAQ:HOLX]’s Current Ratio is 3.89. On the other hand, the Quick Ratio is 3.18, and the Cash Ratio is 2.15. Considering the valuation of this stock, the price to sales ratio is 4.57, the price to book ratio is 3.90 and price to earnings (TTM) ratio is 36.77.
Transactions by insiders
Recent insider trading involved GARRETT SCOTT T, Director, that happened on Mar 14 ’24 when 16441.0 shares were sold. Director, CRAWFORD SALLY completed a deal on Mar 08 ’24 to sell 9039.0 shares. Meanwhile, Director Dockendorff Charles J sold 1465.0 shares on Mar 08 ’24.
